Metreleptin in Anorexia Nervosa
Gabriella Milos · Anorexia Nervosa
Phase 2
Recruiting
50
2026-07
Evidence dashboardStudies since 2001Updated Jul 31, 2026
MetreleptinClinical Trials.
A source-linked view of every Metreleptin study in the current snapshot—status, phase, enrollment, results, publications, locations and changes over time.
- Total trials
- 40
- Recruiting
- 5
- Completed
- 24
- Terminated
- 4
- Results posted
- 25
- Average enrollment
- 56
- Countries
- 14
- Highest phase
- Phase 4
Largest indexed study
636 participants · NCT00673387 →Developer / research origin
Amryt Pharma
Evidence summary
Activity is not efficacy.
Metreleptin appears in 40 indexed studies: 5 recruiting, 24 completed and 25 with registry results posted. The highest registered development stage in this snapshot is Phase 4. These counts measure registry activity; they do not establish that Metreleptin is safe or effective.
Review the design, endpoints, population, protocol changes, statistical analysis and publications before drawing conclusions.
Current studies
Recruiting or active
Completed studies
Finished records
Stopped studies
Withdrawn or terminated
NCT IDStudyPhase / statusEnrollmentUpdated
Compassionate Use of Metreleptin in Previously Treated People With Partial Lipodystrophy
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Diabetes · Lipodystrophy
Phase 2
Active, not recruiting
29
2026-07
Compassionate Use of Metreleptin in Previously Treated People With Generalized Lipodystrophy
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Lipodystrophy · Diabetes
Phase 3
Active, not recruiting
24
2026-07
MEASuRE: Metreleptin Effectiveness And Safety Registry
Chiesi Farmaceutici S.p.A. · Generalised Lipodystrophy · Partial Lipodystrophy
Not applicable
Recruiting
100
2026-07
Open-label Extension Study to Evaluate Metreleptin in Patients With Partial Lipodystrophy
Chiesi Farmaceutici S.p.A. · Familial Partial Lipodystrophy
Phase 3
Recruiting
24
2026-07
Study to Evaluate the Safety and Efficacy of Daily Subcutaneous Metreleptin Treatment in Subjects With PL
Chiesi Farmaceutici S.p.A. · Partial Lipodystrophy
Phase 3
Active, not recruiting
69
2026-06
Showing 6 of 10 studies
NCT IDStudyPhase / statusEnrollmentUpdated
A Study of the Safety of Mibavademab in Pediatric and Adult Participants Switching From Metreleptin to Mibavademab for the Treatment of Generalized Lipodystrophy (GLD)
Regeneron · Generalized Lipodystrophy
Phase 3
Completed
9
2026-07
Immunogenicity of Metreleptin in Patients With Generalized Lipodystrophy
Aegerion Pharmaceuticals, Inc. · Generalized Lipodystrophy
Phase 4
Completed
11
2025-11
Trial of Leptin Replacement Therapy in Patients With Lipodystrophy
University of Texas Southwestern Medical Center · Hypoleptinemia · Generalized Lipodystrophy
Phase 2 / Phase 3
Completed
25
2024-03
The Effects of Metreleptin in Congenital Leptin Deficiency
Northwestern University · Congenital Leptin Deficiency (Disorder)
Not applicable
Completed
2
2021-12
CLINICAL PROTOCOL to Investigate the Long-term Safety and Efficacy of Metreleptin in Various Forms of Partial Lipodystrophy
University of Michigan · Familial Partial Lipodystrophy · Nonalcoholic Steatohepatitis
Phase 2
Completed
11
2020-11
Effects of Human Leptin Replacement
University of Miami · Obesity · Metabolic Syndrome
Phase 2
Completed
3
2020-02
Showing 6 of 24 studies
NCT IDStudyPhase / statusEnrollmentUpdated
Open-label Study to Evaluate Metreleptin in Children Under 6 Years of Age With Generalised Lipodystrophy
Amryt Pharma · Generalized Lipodystrophy
Phase 3
Terminated
1
2026-07
Leptin in Human Energy and Neuroendocrine Homeostasis
Columbia University · Obesity · Weight Loss
Not applicable
Terminated
22
2019-09
Effects of Metreleptin in Type 1 Diabetes Mellitus
University of Texas Southwestern Medical Center · Type 1 Diabetes
Phase 1
Terminated
8
2019-08
A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects
AstraZeneca · Obesity
Phase 2
Terminated
213
2015-04
Full study index
Search Metreleptin trials.
Add status, phase, condition, country, result and publication filters inside this molecule’s indexed study set.
40 matching studies
Last registry update first
Latest publications
Follow the paper trail.
PMID 31314093 ↗Akinci B, Oral EA, Neidert A, Rus D, Cheng WY, Thompson-Leduc P, Cheung HC, Bradt P, Foss de Freitas MC, Montenegro RM, Fernandes VO, Cochran E, Brown RJ. Comorbidities and Survival in Patients With Lipodystrophy: An International Chart Review Study. J Clin Endocrinol Metab. 2019 Nov 1;104(11):5120-5135. doi: 10.1210/jc.2018-02730.Linked from NCT02262806PMID 31194872 ↗Sekizkardes H, Cochran E, Malandrino N, Garg A, Brown RJ. Efficacy of Metreleptin Treatment in Familial Partial Lipodystrophy Due to PPARG vs LMNA Pathogenic Variants. J Clin Endocrinol Metab. 2019 Aug 1;104(8):3068-3076. doi: 10.1210/jc.2018-02787.Linked from NCT02262806PMID 28324110 ↗Brown RJ, Meehan CA, Cochran E, Rother KI, Kleiner DE, Walter M, Gorden P. Effects of Metreleptin in Pediatric Patients With Lipodystrophy. J Clin Endocrinol Metab. 2017 May 1;102(5):1511-1519. doi: 10.1210/jc.2016-3628.Linked from NCT02262806PMID 30847226 ↗Malandrino N, Reynolds JC, Brychta RJ, Chen KY, Auh S, Gharib AM, Startzell M, Cochran EK, Brown RJ. Visceral fat does not contribute to metabolic disease in lipodystrophy. Obes Sci Pract. 2019 Jan 24;5(1):75-82. doi: 10.1002/osp4.319. eCollection 2019 Feb.Linked from NCT02262832PMID 30237235 ↗Meral R, Ryan BJ, Malandrino N, Jalal A, Neidert AH, Muniyappa R, Akinci B, Horowitz JF, Brown RJ, Oral EA. "Fat Shadows" From DXA for the Qualitative Assessment of Lipodystrophy: When a Picture Is Worth a Thousand Numbers. Diabetes Care. 2018 Oct;41(10):2255-2258. doi: 10.2337/dc18-0978.Linked from NCT02262832PMID 37237416 ↗Haymond MW, Araujo-Vilar D, Balser J, Lewis JH, Louzado R, Musso C, von Schnurbein J, Wabitsch M; MEASuRE group. The Metreleptin Effectiveness and Safety Registry (MEASuRE): concept, design and challenges. Orphanet J Rare Dis. 2023 May 26;18(1):127. doi: 10.1186/s13023-023-02714-5.Linked from NCT02325674PMID 32191645 ↗Sekizkardes H, Chung ST, Chacko S, Haymond MW, Startzell M, Walter M, Walter PJ, Lightbourne M, Brown RJ. Free fatty acid processing diverges in human pathologic insulin resistance conditions. J Clin Invest. 2020 Jul 1;130(7):3592-3602. doi: 10.1172/JCI135431.Linked from NCT00085982PMID 37595266 ↗Okawa MC, Tuska RM, Lightbourne M, Abel BS, Walter M, Dai Y, Cochran E, Brown RJ. Insulin Signaling Through the Insulin Receptor Increases Linear Growth Through Effects on Bone and the GH-IGF-1 Axis. J Clin Endocrinol Metab. 2023 Dec 21;109(1):e96-e106. doi: 10.1210/clinem/dgad491.Linked from NCT00085982
Related pages
Keep researching Metreleptin.
Commercial research listings, where present, are kept separate from clinical evidence and are not treatment recommendations.